Bossy Show

Brew Markets

CFO Brew

Morning Brew

Double Shot

Tech Brew

Future Social

Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed.

Healthcare Brew

HR Brew

Incrypto

IT Brew

Marketing Brew

Money Scoop

Money With Katie

Raise

Retail Brew

Sidekick

The Playbook

What healthcare professionals should know about Ozempic

“Our technology can automate a lot of the clerical work that crushes my soul at night as a cardiologist.”

–Shivdev Rao, co-founder of Abridge

How Abridge uses generative AI to reduce clinician burnout

Read about the current state of healthcare employees, the warning signs of compassion fatigue, how to cope with burnout, and how hospital administration can support staff.

Navigating the realities of burnout and compassion fatigue in the healthcare industry

Bench to Bedside & Beyond: The Future of Health Tech

Reducing Friction Through a Modernized Claims Payment Experience

Is New Technology Building a Bridge or Barrier in Access to Healthcare?

Latest

News

Explainers

Analysis

Profiles

Process

Women's health

Staffing

Medicaid

Digital Health

Weight loss

Abortion

Telehealth

Venture Capital

Covid-19

Read stories about the freshest topics in healthcare

Payers

Tech

Startups

Pharma

Hospitals & Facilities

Direct Care

Deep Dives

Register for upcoming events or check out our on-demand library

IRL Events

Webinars

Virtual Events

Subscribe to Healthcare Brew to get healthcare industry news you'll actually want to read

Hospitals and Facilities

Topics

Long-form

State of the Industry: Hospitals

Industry Profiles

Resources

Events

Pharma companies are using digital twins to streamline clinical trials. 

Morning Brew Creative Studio

Caroline Catherman

Nicole Ortiz

Charlotte Hu

Morning Brew logo next to a phone showing the Morning Brew Daily newsletter

After taking a series of economic hits, the retailer is allegedly in talks to sell to PE firm Sycamore Partners.

Walgreens reportedly to sell to private equity firm

Illustration: Anna Kim, Photos: Adobe Stock

On November 25, Cassava Sciences ended a Phase 3 trial of its controversial Alzheimer’s drug, simufilam, following years of scrutiny.

RIP simufilam, we hardly knew ye 

A look at the ways the drugmaker has applied digital twin technology in its clinical studies.

MBCS

Morning Brew Creative Studio